Sustainability | November 01, 2024
Lupin to develop inhalers with near-zero global warming potential propellants
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Poor oral health (periodontal disease) impacts nearly 51% of Indians
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
The net-zero target approval complements the company's near-term emission reduction targets
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Subscribe To Our Newsletter & Stay Updated
